Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Total Non-Current Liabilities (2021 - 2024)

Aligos Therapeutics' Total Non-Current Liabilities history spans 4 years, with the latest figure at $26.7 million for Q4 2024.

  • For Q4 2024, Total Non-Current Liabilities fell 16.17% year-over-year to $26.7 million; the TTM value through Dec 2024 reached $26.7 million, down 16.17%, while the annual FY2024 figure was $26.7 million, 16.17% down from the prior year.
  • Total Non-Current Liabilities reached $26.7 million in Q4 2024 per ALGS's latest filing, roughly flat from $26.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $57.4 million in Q1 2022 to a low of $26.1 million in Q1 2024.
  • Average Total Non-Current Liabilities over 4 years is $38.7 million, with a median of $40.5 million recorded in 2021.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 47.11% in 2022, then decreased 16.17% in 2024.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $50.5 million in 2021, then dropped by 16.99% to $41.9 million in 2022, then decreased by 24.02% to $31.9 million in 2023, then fell by 16.17% to $26.7 million in 2024.
  • Per Business Quant, the three most recent readings for ALGS's Total Non-Current Liabilities are $26.7 million (Q4 2024), $26.7 million (Q3 2024), and $30.1 million (Q2 2024).